Axon’s sell-off still looks like a valuation tantrum, not a thesis break. The core reason is simple: the operating engine keeps accelerating even as the stock gets repriced. In the latest quarter, revenue climbed 34% year over year to $807 million, ARR reached $1.5 billion with 35% growth, and management raised full-year revenue growth guidance to 30% to 32% from 27% to 30%. When a company is still putting up those numbers, a pullback says more about the multiple than the business.
The cleanest bull point is that demand has not cracked. Axon’s software and services revenue rose 35% year over year to $355 million in Q1, and that matters because recurring software revenue is what gives this story its premium. ARR at $1.5 billion, also up 35%, says customers are not backing away from the platform. Add in AI products growing more than 700% year over year, and the market is looking at a company with fresh monetization legs, not one running out of runway.
Management’s own outlook makes the sell-off harder to read as a fundamental warning. Axon raised 2026 revenue growth guidance to 30% to 32% while keeping its 25.5% adjusted EBITDA margin target intact. That is the combination bulls want to see: faster top-line expectations without a margin walk-back. The backlog also supports that view, with total future contracted bookings ending 2025 at $14.4 billion, up 43% year over year, giving the company a sizable cushion against any claim that demand is suddenly rolling over.
The tape also looks more like digestion than collapse. AXON is still above its 50-day moving average of $470.18 even after the recent weakness, and on-balance volume is still flagged as accumulation. News sentiment has remained strongly positive, with 7-day sentiment at 0.9945, and consensus estimates still lean heavily constructive with 17 buys against 4 holds and no sells. That does not mean the stock is cheap; it means the market is still treating Axon like a secular compounder even while trimming the premium.
The obvious problem is valuation, and it is a real one. AXON trades at 197.35 times trailing earnings, 13.77 times sales, and 109.89 times EV/EBITDA, which is miles above industrial peers like LHX at 25.60 times earnings and 2.34 times sales or FDX at 15.49 times earnings and 0.79 times sales. The TickerSpark Score captures that tension cleanly: a middling 53 overall with a weak 36 on Valuation despite better marks in Profitability and Financial Health. This stock does not need bad results to fall; it only needs expectations to cool.
The income statement also gives skeptics ammunition. Operating margin is just 1.3%, net margin is 6.9%, and trailing EPS growth is down 67.9% year over year, so the market is paying up for future scale more than present earnings power. Insider activity is not a bullish tell either, with no recent buys and small CEO selling on July 7. Even so, those are the risks of an expensive winner, not the fingerprints of a broken demand story, and that distinction matters.
That leaves AXON in a spot where we would lean bullish, but with discipline. This is not a stock to own because it looks statistically cheap; it is a stock to own because the business keeps outrunning the fear. As long as revenue growth stays around the current 30%-plus range, ARR keeps compounding, and management avoids cutting guidance, the recent weakness looks buyable rather than ominous.
What would change our mind is straightforward: a quarter that shows clear deceleration without another guidance raise, or evidence that AI enthusiasm is not converting into durable software growth. Until then, the underperformance versus Industrials this year looks more like a reset in what investors are willing to pay than a signal that Axon’s growth machine has stalled.
